IPO - ALLURION TECHNOLOGIES, INC.

Form Type: 424B5

Filing Date: 2025-02-20

Corporate Action: Ipo

Type: New

Accession Number: 000119312525030196

Filing Summary: Allurion Technologies, Inc. is offering 900,000 shares of its common stock to accredited investors at an offering price of $5.23 per share, accompanied by warrants to purchase additional shares. The warrants become exercisable upon obtaining stockholder approval for the underlying shares, and will expire five years post-approval. A concurrent private placement involves Leavitt Equity Partners III purchasing 267,686 shares at the same price, secured by accompanying warrants for twice the number of shares. The closing of both the public offering and the private placement are independent of each other. The company aims to raise approximately $4.7 million, with net proceeds expected to be $4.377 million after agent fees. The common stock and public warrants are currently listed on the NYSE. The aggregate market value of Allurion’s common stock held by non-affiliates is noted as $36.4 million. Allurion is defined as an

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-01-27

Corporate Action: Ipo

Type: New

Accession Number: 000119312525012785

Filing Summary: Allurion Technologies, Inc. is offering 1,240,000 shares of common stock at a price of $6.00 per share to certain accredited investors, with concurrent issuance of common warrants. The warrants will become exercisable upon stockholder approval, which has not yet been obtained. The last reported sale price of the common stock was $8.69 prior to this offering. The offering is being managed by Roth Capital Partners, LLC as the exclusive placement agent. The company expects to deliver the securities on January 27, 2025, pending customary closing conditions. Additionally, a reverse stock split has recently taken place at a ratio of 1-for-25, thereby reclassifying shares. The offering proceeds will be used to support Allurion's operations, including further advancements in its weight loss program and its collaboration with Medtronic. The company has also reported promising trial results for its Allurion Balloon device, further strengthening its market position and future prospects.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-13

Corporate Action: Ipo

Type: Update

Accession Number: 000119312525005199

Filing Summary: This filing relates to Allurion Technologies, Inc.'s registration statement regarding an initial public offering (IPO) of its common stock. The document details adjustments made to the weighted-average common shares and net loss per share calculations in relation to the Business Combination and the Reverse Stock Split. Significant past periods have been retrospectively adjusted to reflect the number of shares that would have been outstanding after these corporate actions. The adjustments are necessary to provide accurate financial representations for investors considering the IPO. Further details about the adjustments and financial impact are elaborated in Notes 1 and 3 of the filing, and additional information regarding the company’s financial performance and potential risks are included throughout the document.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-08

Corporate Action: Ipo

Type: New

Accession Number: 000119312525003222

Filing Summary: Allurion Technologies, Inc. has filed an amendment to their Form S-1 registration statement in relation to their upcoming initial public offering (IPO). The filing includes updated financial statements reflecting their operations and adjustments made after a business combination, which involved retrospective adjustments for weighted-average common shares and net loss per share calculations following a reverse capitalization and a reverse stock split. The document provides detailed discussion on the financial condition and results of operations for periods concluding on September 30, 2024, and includes comprehensive information on share structure, outstanding warrants, and preferred stock among other securities. It highlights developments in the terms of various financing agreements and addresses risk factors pertinent to the business and its market environment, essential for potential investors to evaluate before participating in the IPO.

Document Link: View Document